TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7506013

Group type: EXPERIMENTAL
Intervention: Iloprost (0.5 to 2.0 ng/kg per min)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 131
Study: 3141856

Group type: EXPERIMENTAL
Intervention: Gamma-interferon (100 micrograms/m2 3x/week for 4 h i.v. every other week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gamma-interferon (500 micrograms/m2 5x/week for 24 h i.v. every other week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-2-interferon (18 x 10(6) U 3x/week weekly i.m.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-2-interferon in combination with vinblastine (0.1 mg/kg every third week i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gamma-interferon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-2-interferon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with objective tumor response
Number of subjects: 0
Study: 30342969

Group type: EXPERIMENTAL
Intervention: Data-sharing agreement
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 247
Study: 27803118

Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin plus lifestyle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (baseline comparison)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (treatment failure comparison)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (temporal changes)
Number of subjects: 0
Study: 26141467

Group type: EXPERIMENTAL
Intervention: 13 mL 10% tPA
Number of subjects: 62

Group type: COMPARATOR
Intervention: 13 mL normal saline
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: tPA
Number of subjects: 62
Study: 23088627

Group type: EXPERIMENTAL
Intervention: EndoREZ
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: iRoot SP
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sealapex
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 80
Study: 20506261

Group type: EXPERIMENTAL
Intervention: Non-aspirin NSAIDs
Number of subjects: 6059

Group type: EXPERIMENTAL
Intervention: All NSAIDs
Number of subjects: 6059

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 6059

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 6059

Group type: COMPARATOR
Intervention: Aspirin, NSAID, and paracetamol use
Number of subjects: 6059
Study: 19076728

Group type: EXPERIMENTAL
Intervention: Combination of vitamin C and BH(4)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 16399293

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery
Number of subjects: 511
Study: 15527634

Group type: EXPERIMENTAL
Intervention: Peri‐Strips Dry (Group A, n=50)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control (Group B, n=48)
Number of subjects: 98
Study: 11442216

Group type: EXPERIMENTAL
Intervention: Meglumine antimonate (20 mg Sb/kg/day) for 10 days
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Meglumine antimonate (20 mg Sb/kg/day) for 20 days
Number of subjects: 82

Group type: COMPARATOR
Intervention: Children < 5 years in 10-day group
Number of subjects: 82

Group type: COMPARATOR
Intervention: Children < 5 years in 20-day group
Number of subjects: 82

Group type: COMPARATOR
Intervention: Patients aged 5-14 years in 10-day group
Number of subjects: 82

Group type: COMPARATOR
Intervention: Patients aged 5-14 years in 20-day group
Number of subjects: 82

Group type: COMPARATOR
Intervention: Patients aged 15 years or more in 10-day group
Number of subjects: 82

Group type: COMPARATOR
Intervention: Patients aged 15 years or more in 20-day group
Number of subjects: 82
Study: 10351142

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) plus prednisone (n=13; 10 with albumin, 3 with FFP)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Prednisone alone (n=10)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Number of subjects: 23
Study: 8061763

Group type: EXPERIMENTAL
Intervention: Injection pen for growth hormone administration (Nordiject)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.9% benzyl alcohol solvent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30G needle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automatic needle insertion device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual needle insertion device
Number of subjects: 0
Study: 2853731

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (600 mg/day) for 4 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29474546

Group type: EXPERIMENTAL
Intervention: Thrice-weekly intervention messages, plus texted primary care appointment reminders and a monthly text message requesting confirmation of study participation
Number of subjects: 230

Group type: COMPARATOR
Intervention: Texted reminders and monthly messages alone
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Thrice-weekly intervention messages
Number of subjects: 230
Study: 28447460

Group type: EXPERIMENTAL
Intervention: Histidine supplementation
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 24856961

Group type: EXPERIMENTAL
Intervention: Optimized CTZ microspheres
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marketed CTZ product
Number of subjects: 0
Study: 24524605

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study: 21691166

Group type: EXPERIMENTAL
Intervention: Single-balloon catheter
Number of subjects: 293

Group type: COMPARATOR
Intervention: Double-balloon catheter
Number of subjects: 293
Study: 18475164

Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 9131
Study: 12601097

Group type: EXPERIMENTAL
Intervention: Surgical resection of medial frontal lesions involving the supplementary motor area (SMA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Preoperative fMRI assessment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Surgical resection involving SMA
Number of subjects: 12
Study: 9857618

Group type: EXPERIMENTAL
Intervention: ELISA test for detection of antibodies against pertussis toxin
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Passive haemagglutination test with B. pertussis endotoxin
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (children without respiratory infections)
Number of subjects: 127
Study: 7634134

Group type: EXPERIMENTAL
Intervention: Mouthrinse with 0.2% chlorhexidine (CHX) and 0.3% triclosan in soya oil, used twice daily for 4 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control (water)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mouthrinse with aqueous phase containing chlorhexidine combined with oily phase without triclosan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-phase mouthrinse with soya oil containing 0.3% triclosan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.1% CHX alone in water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soya oil without triclosan
Number of subjects: 0
Study: 2677081

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.6 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 148936

Group type: EXPERIMENTAL
Intervention: 3 mg of phenytoin/kg body weight/day for five days followed by 6 mg/kg body weight/day (group 1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6 mg of phenytoin/kg body weight/day for five days followed by 6 mg/kg body weight/day (group 2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Phenytoin concentration higher than 14 micromol/l on day 5
Number of subjects: 10
Study: 30603800

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS to unaffected hemisphere
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional dysphagia rehabilitation
Number of subjects: 28
Study: 28265014

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC), 4 cycles within 24 hours of ictus
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham (placebo)
Number of subjects: 26
Study: 25822861

Group type: EXPERIMENTAL
Intervention: Gel hypotonic super-ORS containing zinc (group 2)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard hypotonic ORS (group 1)
Number of subjects: 83
Study: 23799163

Group type: EXPERIMENTAL
Intervention: Rhinophototherapy with topical mometasone furoate 200 mcg/day and levocetirizine 5 mg/day, applied twice a week for three weeks.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Topical mometasone furoate 200 mcg/day and levocetirizine 5 mg/day (Control group).
Number of subjects: 65
Study: 21075562

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Standard practice classroom-delivered Drug Awareness intervention
Number of subjects: 416
Study: 19996663

Group type: EXPERIMENTAL
Intervention: Epidural/general anesthesia (0.5% bupivacaine with sevoflurane)
Number of subjects: 54

Group type: COMPARATOR
Intervention: General anesthesia (sevoflurane and intravenous fentanyl)
Number of subjects: 54
Study: 17299473

Group type: COMPARATOR
Intervention: LFD
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: LCKD
Number of subjects: 39
Study: 15303633

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg once daily for 5 days
Number of subjects: 360

Group type: COMPARATOR
Intervention: Levofloxacin 500 mg once daily for 7 days
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Number of subjects: 360

Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 360
Study: 11344347

Group type: COMPARATOR
Intervention: Inhaled budesonide (withdrawal group)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Healthy children (reference group)
Number of subjects: 33
Study: 9484875

Group type: EXPERIMENTAL
Intervention: Grepafloxacin 400 mg od
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Grepafloxacin 600 mg od
Number of subjects: 656

Group type: COMPARATOR
Intervention: Amoxycillin 500 mg tds
Number of subjects: 656
Study: 7910229

Group type: EXPERIMENTAL
Intervention: Lisinopril (5 mg initial dose, then 10 mg daily)
Number of subjects: 18934

Group type: COMPARATOR
Intervention: Transdermal glyceryl trinitrate (GTN, 10 mg daily after intravenous for the first 24 hours)
Number of subjects: 18934

Group type: EXPERIMENTAL
Intervention: Combined administration of lisinopril and GTN
Number of subjects: 18934
Study: 29562612

Group type: EXPERIMENTAL
Intervention: Comprehensive nutritional and dietary intervention including vitamin/mineral supplements, essential fatty acids, Epsom salt baths, carnitine, digestive enzymes, and a healthy gluten‐free, casein‐free, soy‐free (HGCSF) diet
Number of subjects: 67

Group type: COMPARATOR
Intervention: Non-treatment group (control)
Number of subjects: 67
Study: 27430332

Group type: EXPERIMENTAL
Intervention: EuroFIT program (lifestyle intervention) delivered over 12 weekly, 90-minute sessions combining classroom discussion with graded physical activity.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: EuroFIT program (lifestyle intervention)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness assessment of the EuroFIT program
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Process evaluation of the EuroFIT program
Number of subjects: 1000
Study: 25335331

Group type: EXPERIMENTAL
Intervention: Acupoint massage dominant early comprehensive intervention
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (routine therapy only)
Number of subjects: 210
Study: 22733983

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) with Medtronic CoreValve prosthesis (CVP)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Pre-operative abnormal conduction (first degree AV block and left bundle branch block)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Age >75 years
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Pre-operative heart rate <65 beats per minute
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: CVP oversizing >4 mm
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: CVP prosthesis >26 mm
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Ventricular rate <65 beats per minute at the first post-operative day
Number of subjects: 88
Study: 20447613

Group type: EXPERIMENTAL
Intervention: 0.02% polyhexamethylene biguanide (PHMB)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 19050308

Group type: EXPERIMENTAL
Intervention: Fludarabine, cyclophosphamide, and rituximab (FCR)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Subsequent chemoimmunotherapy protocols
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Unmutated IgV(H)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Mutated IgV(H)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: IgV(H) MS
Number of subjects: 304
Study: 16961684

Group type: EXPERIMENTAL
Intervention: Home delivery service (HDS) for essential dietary products (EDP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (traditional system)
Number of subjects: 62
Study: 15615033

Group type: EXPERIMENTAL
Intervention: Mobile ECG device with integrated electrodes; patients record three special leads and send data via cellular phone.
Number of subjects: 0
Study: 11083258

Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 156
Study: 9157579

Group type: EXPERIMENTAL
Intervention: Desirudin (10, 15, or 20 mg bid)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU tid)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 159
Study: 8143568

Group type: EXPERIMENTAL
Intervention: Nonrigid reclining infant seat (3‐h sessions, twice a day for 6‐ to 7‐week period)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 3519825

Group type: EXPERIMENTAL
Intervention: Lactation nurse support during early weeks after parturition
Number of subjects: 649

Group type: COMPARATOR
Intervention: Control group (no lactation nurse support)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Lactation nurse support
Number of subjects: 649
Study: 29209863

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - One-time clinical medication review
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control Group (CG) - Usual care
Number of subjects: 145
Study: 26802945

Group type: EXPERIMENTAL
Intervention: Aggressive rehabilitation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 39
Study: 23921559

Group type: EXPERIMENTAL
Intervention: Orthogonal plating
Number of subjects: 67

Group type: COMPARATOR
Intervention: Parallel plating
Number of subjects: 67
Study: 21916526

Group type: EXPERIMENTAL
Intervention: ABVD regimen
Number of subjects: 140

Group type: COMPARATOR
Intervention: BEACOPP and CEC regimens
Number of subjects: 140
Study: 20539277

Group type: EXPERIMENTAL
Intervention: TT homozygous men with treated hypertension
Number of subjects: 2836

Group type: COMPARATOR
Intervention: C allele carriers
Number of subjects: 2836
Study: 18294268

Group type: EXPERIMENTAL
Intervention: PC-SOD 40 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PC-SOD 80 mg
Number of subjects: 42
Study: 16047459

Group type: EXPERIMENTAL
Intervention: High-dose omeprazole (200 mg/day)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Low-dose omeprazole (80 mg/day)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: High-dose and low-dose omeprazole
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Serum albumin level <3 g/dL
Number of subjects: 105
Study: 12445227

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine‐alcohol mouthrinse (CHX‐Alc)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.05% CHX + 0.05% cetylpyridinium chloride + 0.14% zinc lactate mouthrinse (CHX‐CPC‐Zn)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (125 ppm F‐/125 ppm F‐) mouthrinse (AmF/SnF2Mr)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Slurry of toothpaste containing amine fluoride (350 ppm F‐) and stannous fluoride (1050 ppm F‐) (AmF/SnF2Sl)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 16
Study: 10515650

Group type: EXPERIMENTAL
Intervention: Active non-steroidal anti-inflammatory drug (NSAID) for 6 weeks
Number of subjects: 473

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 473
Study: 8536776

Group type: EXPERIMENTAL
Intervention: TER 5 mg once in the morning (AM)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: TER 5 mg once in the evening (PM)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: DOX 4 mg once in the morning (AM)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: DOX 4 mg once in the evening (PM)
Number of subjects: 43
Study: 1775604

Group type: EXPERIMENTAL
Intervention: Tacrine (THA), a cholinesterase inhibitor
Number of subjects: 0
Study: 7274074

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (Elipten) 250-1500 mg/d by mouth
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide in combination with cytostatic drugs
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide
Number of subjects: 17
Study: 30649551

Group type: EXPERIMENTAL
Intervention: Modified Assessment of SpondyloArthritis international Society-RS
Number of subjects: 3877

Group type: EXPERIMENTAL
Intervention: EpiReumaPt-RS
Number of subjects: 3877

Group type: COMPARATOR
Intervention: Other RSs
Number of subjects: 3877

Group type: EXPERIMENTAL
Intervention: Positive RS
Number of subjects: 3877
Study: 28657769

Group type: EXPERIMENTAL
Intervention: Monurelle Biogel® vaginal gel
Number of subjects: 95

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 95
Study: 26312777

Group type: EXPERIMENTAL
Intervention: Conventional CXL (Dresden protocol)
Number of subjects: 43

Group type: COMPARATOR
Intervention: CXL with mechanical compression (CRXL)
Number of subjects: 43
Study: 23706506

Group type: EXPERIMENTAL
Intervention: Gradual training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sudden training
Number of subjects: 16
Study: 21345571

Group type: EXPERIMENTAL
Intervention: Difficult intubation (IDS >5)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Complications within 5 min of intubation
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Intubation difficulty (IDS score)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Difficult intubation
Number of subjects: 650
Study: 19064978

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 439
Study: 17575680

Group type: EXPERIMENTAL
Intervention: 2HRZE3/6HE regimen (thrice-weekly direct dosing in the intensive phase and once-weekly with six doses self-administered in the continuation phase)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 2HRZE3/6HE regimen
Number of subjects: 450
Study: 15248627

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg orally 1 h before operation and again at 6 and 12 h after the initial dose.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g orally at the same time intervals as ibuprofen.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combination of ibuprofen 800 mg and acetaminophen 1 g.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (Acetaminophen group).
Number of subjects: 61
Study: 10855913

Group type: EXPERIMENTAL
Intervention: Supported discharge after an acute admission
Number of subjects: 9
Study: 9030833

Group type: EXPERIMENTAL
Intervention: Vitamin D receptor genotype
Number of subjects: 69
Study: 8315263

Group type: EXPERIMENTAL
Intervention: Torasemide (20 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Furosemide (80 mg)
Number of subjects: 14
Study: 3548346

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma infusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Stored plasma infusion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Daily infusion of 1,000 ml of fresh frozen plasma for 7 to 18 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Paracentesis to reduce intraperitoneal pressure
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Placement of a LeVeen shunt
Number of subjects: 11
Study: 31409130

Group type: EXPERIMENTAL
Intervention: Lachin-Foulkes adjustment to sample size and noninferiority margin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lachin-Foulkes adjustment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonrandom nonadherence associated with a prognostic risk score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed sensitivity analysis
Number of subjects: 0
Study: 28162769

Group type: EXPERIMENTAL
Intervention: Cord blood placental growth factor (PIGF)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Cord blood granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Receiver operator curve analysis for PIGF
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Receiver operator curve analysis for G-CSF
Number of subjects: 190
Study: 25884885

Group type: EXPERIMENTAL
Intervention: MOVI-KIDS (intervention group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (control group)
Number of subjects: 21
Study: 23945890

Group type: COMPARATOR
Intervention: Polyvinyl chloride cuff (PVC) ETT
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Polyurethane cylindrical Sealguard ETT
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Polyurethane Taperguard ETT
Number of subjects: 96
Study: 21210279

Group type: EXPERIMENTAL
Intervention: Treadmill 100-m sprint
Number of subjects: 11

Group type: COMPARATOR
Intervention: Field 100-m sprint
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Treadmill and field performance comparison
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 11
Study: 20008210

Group type: EXPERIMENTAL
Intervention: Statin medications
Number of subjects: 1